Latest news with #VENT-01

National Post

Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference

Article content WALTHAM, Mass. & MONTREAL — Ventus Therapeutics, a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders, today announced that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference, being held May 5-6 in Toronto. Dr. Bigal will be presenting on Tuesday, May 6, at 1:30 p.m. ET. Article content Article content Ventus Therapeutics is a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders. Using its proprietary drug discovery platform, ReSOLVE ®, the company has established a robust pipeline, including two wholly-owned programs. VENT-03 is a first-in-class, oral cGAS inhibitor expected to enter Phase 2 development for lupus in 2025. VENT-02 is a best-in-class, brain-penetrant, oral NLRP3 inhibitor in Phase 2 for Parkinson's disease, and is expected to enter Phase 2 development for osteoarthritis in obese patients later in 2025. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted, oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S. For more information, please visit and engage with Ventus on LinkedIn. Article content Article content Article content Article content Article content Contacts Article content Article content